Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating Activities
Net loss	$ (40,933)	$ (21,431)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,065	2,066
Gain on disposal of property and equipment		(14)
Depreciation and amortization	1,007	1,439
Accretion of premium on short term investments	(1,385)	(468)
Change in fair value of contingent consideration liability	108	876
Changes in operating assets and liabilities:
Accounts receivable - collaboration agreement	194	8,478
Prepaid expenses	1,233	652
Other current assets	464	(325)
Operating lease liabilities	(97)	(29)
Accounts payable	1,422	(3,237)
Change in contingent consideration liability		(1,289)
Accrued compensation and other accrued liabilities	2,445	1,002
Other non-current assets	92	(275)
Deferred revenue		(19,306)
Net cash flows used in operating activities	(33,385)	(31,861)
Investing Activities
Proceeds from maturities of short-term investments	40,000	35,500
Purchase of short-term investments	(6,740)	(15,228)
Proceeds from sale of property and equipment	25	193
Purchases of property and equipment	(249)	(990)
Net cash flows provided by investing activities	33,036	19,475
Financing Activities
Payments of financing costs	(92)
Payment of contingent consideration related to Myst milestone		(898)
Payment of deferred IPO costs		(269)
Proceeds from exercise of stock options	44	86
Net cash flows used in financing activities	(48)	(1,081)
Net decrease in cash, cash equivalents and restricted cash	(397)	(13,467)
Cash, cash equivalents and restricted cash at beginning of the period	17,914	35,113
Cash, cash equivalents and restricted cash at end of the period	17,517	21,646
Supplemental Disclosure of Cash Flow Information:
Cash paid for income taxes	119
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Accretion of redeemable convertible preferred stock		39
Equipment purchases included in accrued expenses		186
Financing costs included in accounts payable	$ 28
Deferred IPO costs included in accrued expenses		$ 2,286